Advancing Selective & Safe Ion Channel Drugs Across Indications Through Automated Electrophysiology, Structural Assays & Translatability Insights to Fulfil Unmet Patient Needs
The ion channel field is gaining renewed momentum. Advances in cryo-EM, automated electrophysiology, and computational modelling are unlocking a historically complex target class, while recent clinical successes and increased biopharma investment are accelerating pipelines across CNS, cardiovascular, renal, and emerging indications. With new modalities entering the clinic and a growing understanding of channel biology, ion channel drug discovery is entering a critical phase of innovation and opportunity.
As the first industry-led, modality and indication-agnostic meeting, the Ion Channel-Targeted Drug Development Summit brings together leading innovators from across biopharma and academia, including Nocion Therapeutics, Maxion Therapeutics,Mair Therapeutics,Navega Therapeutics, Quiver Biosciences, GSK, Harvard Medical School, and Brown University, to share the latest advances in discovery, translational science, and clinical development.
Join ion channel-focused experts to exchange insights, build collaborations, and accelerate the next generation of therapeutics from discovery to clinic.
This meeting will bring together a wide range of preclinical and clinical expertise in ion channel drug discovery and development, offering a key opportunity to hear from and meet scientists from across the globe who share a passion for understanding the role of ion channels in human disease and using this to discover and progress new treatments.
Marc Rogers, Drug Discovery Consultant, Albion Drug Discovery Services Ltd
There have been tremendous advances in the clinical development of novel therapeutics selectively targeting ion channels. We are excited to learn of these advances and to share our data on taplucainiumin rCC with the ion channel community.
Jim Ellis, Chief Scientific Officer, Nocion Therapeutics
I believe this meeting is valuable, as ion channel drug discovery remains significantly more challenging than many other target classes. Bringing together experts across biology, chemistry, translational science, and drug development creates a unique opportunity to exchange insights, discuss emerging issues, and ultimately accelerate innovation.
Alexei Pushechnikov, Vice President MedChem, Mair Therapeutics
Explore the Full Event Guide
- Get a complete snapshot of the agenda, key topics, and scientific focus areas across discovery to clinic
- Explore the cutting-edge themes shaping ion channel drug discovery, from electrophysiology to structural biology
- Preview the calibre of speakers and leading biopharma companies driving the next wave of innovation
- Understand how the summit tackles critical challenges like selectivity, translatability, and safety in ion channel development
- Easily share key event insights with colleagues to support internal alignment and attendance decisions
Speakers
Official Partners
Attending Companies Include
Explore the Agenda
Dive into cutting-edge ion channel strategies, from electrophysiology to clinical translation, across a data-packed program.
Partner With Us
Showcase your platforms, technologies, and services to senior decision-makers driving ion channel innovation.
Join Ion Channel Leaders
Connect with biopharma pioneers and scientific experts tackling selectivity, safety, and translational challenges head-on.